SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-20-096526
Filing Date
2020-08-18
Accepted
2020-08-18 16:15:20
Documents
5
Period of Report
2020-09-17
Effectiveness Date
2020-08-18

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm2027774-1_def14a.htm DEF 14A 458482
2 GRAPHIC lg_outlook-therapeutics.jpg GRAPHIC 405718
3 GRAPHIC tm2027774d1-px_meetingbw.jpg GRAPHIC 541104
4 GRAPHIC tm2027774d1-px_votingbw.jpg GRAPHIC 702286
5 GRAPHIC tm2027774d1-px_signedbw.jpg GRAPHIC 479103
  Complete submission text file 0001104659-20-096526.txt   3390876
Mailing Address 4260 U.S. ROUTE 1 MONMOUTH JUNCTION NJ 08852
Business Address 4260 U.S. ROUTE 1 MONMOUTH JUNCTION NJ 08852 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

IRS No.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: DEF 14A | Act: 34 | File No.: 001-37759 | Film No.: 201113823
SIC: 2836 Biological Products, (No Diagnostic Substances)